Medivir To Acquire BioPhausia's Commercial Platform To Market HCV Drug

Swedish company Medivir AB, which develops pharmaceuticals against infectious diseases caused by viruses, has made an SEK565 million ($91 million) offer for specialty pharmaceutical company BioPhausia AB. Medivir says that the acquisition of its Swedish compatriot would provide it with a well-established commercial platform from which to launch its hepatitis C drug TMC435, which should be out on the market by 2013.